Bladder Cancer’s Immune Landscape Comes Into Focus

0

1. Study on immunohistochemical classification of MIBC.

2. Evaluated 124 urothelial carcinoma patients.

3. Tumors classified as luminal, basal, other.

4. PD-1 expressed in 70.5 percent of tumors.

5. Higher PD-1 in luminal tumors (84.2 percent).

6. PD-L1 observed in 40 percent of tumors, higher in basal.

7. Study did not assess survival outcomes.

8. Findings may guide therapeutic strategies.